Latest:
Dr Gruenwald on Tumor Responses With Lenvatinib Plus Pembrolizumab in Advanced RCC
Viktor Gruenwald, MD, PhD, discusses key results from a post-hoc analysis of the phase 3 CLEAR trial in advanced renal cell carcinoma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Jules Lin, MD
Latest:
Dr Lin on the Effect of Perioperative Treatment on Surgical Approaches in NSCLC
Jules Lin, MD, discusses how approaches to surgical intervention in non–small cell lung cancer may have shifted with the increasing use of targeted therapy and immunotherapies in the adjuvant and neoadjuvant setting.
Noah Stansfield
Latest:
BASECAMP-1 Trial Aims to Identify Patients With Solid Tumors Who Are Eligible for A2B530
The observational BASECAMP-1 screening study has started to identify patients with advanced solid tumors harboring somatic human leukocyte antigen-A*02 loss of heterozygosity who would be eligible to receive the novel Tmod CAR T-cell therapy, A2B530, if their cancer relapses after standard of care treatment.
Matthew Frank, MD, PhD
Latest:
Dr Frank on the Background of Investigating CAR22 Therapy in Relapsed/Refractory LBCL
Matthew Frank, MD, PhD, discusses findings from prior research investigating a CD22-directed CAR T-cell therapy that informed the rationale for launching a phase 1 trial with this agent in patients with relapsed/refractory large B-cell lymphoma.
Rinath M. Jeselsohn, MD
Latest:
Dr Jeselsohn on Enrollment Criteria For the VERITAC-2 Trial in ER+ Breast Cancer
Rinath M. Jeselsohn, MD, discusses enrollment criteria for the phase 3 VERITAC-2 trial, as well as the potential clinical implications of this research for patients with advanced estrogen receptor–positive/HER2-negative metastatic breast cancer.
Karam Al-Issa, MD
Latest:
Student Loan Debt, Immigration Status Often Drive Career Decisions for Fellows
Investigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.